Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics (NASDAQ: ALLR) has announced its participation in the upcoming Pharma Partnering Summit US, scheduled for May 14-15 in San Diego. CEO Thomas Jensen will present a company overview highlighting their key assets: stenoparib, a Phase 2 dual PARP and WNT pathway inhibitor, and their DRP® companion diagnostic platform. The event serves as a business development and licensing conference for biotech and pharmaceutical executives. Jensen will be available for one-on-one meetings with registered attendees during the summit.
Allarity Therapeutics (NASDAQ: ALLR) has announced the presentation of a new Drug Response Predictor (DRP®) for daratumumab at the 2025 AACR Annual Meeting. The novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab treatment.
The DRP® was developed by analyzing gene expression patterns correlated with daratumumab sensitivity, identifying 53 genes - 27 associated with sensitivity and 26 with resistance. Using data from the KYDAR trial, the DRP demonstrated ability to predict treatment outcomes and survival in multiple myeloma patients.
This marks Allarity's first DRP® developed for an antibody therapy, expanding beyond their previous small-molecule drug predictors. The company currently has stenoparib, a dual PARP and WNT pathway inhibitor, in Phase 2 development for ovarian cancer and small cell lung cancer.
Allarity Therapeutics (NASDAQ: ALLR) reported its full year 2024 financial results, highlighting a strong cash position of $20.9 million as of December 31, 2024, with approximately $25 million at Q1 2025 end. This funding is expected to support operations into 2027.
The company's primary focus is on stenoparib, their dual PARP/WNT pathway inhibitor, which showed promising results in treating heavily pre-treated ovarian cancer patients, with some patients maintaining treatment benefits for over 17 months. Two key clinical trials are planned: a Phase 2 ovarian cancer trial starting H1 2025, and a VA-funded Phase 2 SCLC combination trial beginning Q2-Q3 2025.
Financial highlights include:
- R&D expenses: $6.1 million (down from $7.1 million in 2023)
- G&A expenses: $11.4 million (up from $10.0 million in 2023)
- Net loss: $24.5 million (increased from $11.9 million in 2023)
- Fully utilized ATM program and implemented a $5 million share repurchase program
Allarity Therapeutics (NASDAQ: ALLR) has announced a strategic partnership with Shareholder Intelligence Services (ShareIntel) to investigate potential illegal naked short selling and trading irregularities in its stock. The initiative aims to protect shareholder value and ensure transparent trading practices.
ShareIntel will employ its proprietary DRIL-Down™ technology to analyze trading patterns, monitor potential abuses, and detect unusual short-selling activities. The platform will track data from broker-dealers, clearing firms, and reporting entities to identify possible market manipulation.
The company, currently in Phase 2 clinical trials developing stenoparib (a dual PARP/Wnt pathway inhibitor), will specifically monitor compliance with SEC's Regulation SHO regarding short-selling practices. If violations are detected, Allarity plans to pursue legal action against responsible parties.
Allarity Therapeutics (NASDAQ: ALLR) presented new Phase 2 clinical data for stenoparib in advanced ovarian cancer at the SGO 2025 Annual Meeting. The trial focused on heavily pre-treated patients, with 14 out of 15 participants being platinum-resistant and one having primary platinum-refractory disease.
Key findings show that five patients maintained therapy beyond 4 months, with four exceeding 20 weeks. Notable outcomes include:
- One patient achieved a confirmed complete response lasting over 10 months
- Two patients remain on therapy after 17+ months
- The platinum-refractory patient stayed on therapy beyond 40 weeks
Significantly, stenoparib showed benefit in patients without BRCA mutations, potentially due to its unique dual mechanism inhibiting both PARP and Wnt pathway. The drug demonstrated good tolerability without typical bone marrow toxicity seen in first-generation PARP inhibitors.
Allarity Therapeutics (NASDAQ: ALLR) has reached a final settlement with the SEC regarding its past disclosures about FDA interactions concerning its New Drug Application for Dovitinib. The settlement follows the January 30, 2025 agreement in principle.
Key terms include:
- A $2.5 million civil penalty payment
- A cease-and-desist order without admitting or denying SEC findings
- Findings of violations under Securities Act Sections 17(a)(2) and (3) and Exchange Act Section 13(a)
The company confirms this penalty won't impact its financial outlook or ability to execute planned Phase 2 clinical trials. Allarity's cash position is expected to support operations into 2026. The settlement resolves all outstanding legal matters, including the recently dismissed securities class action lawsuit.
Allarity Therapeutics (NASDAQ: ALLR) has announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide for treating recurrent Small Cell Lung Cancer (SCLC). The trial, fully funded by the U.S. Veterans Administration through the Special Emphasis Panel on Precision Oncology, will be conducted across 11 VA medical centers.
The study will enroll approximately 65 extensive-stage SCLC patients who have failed frontline treatment. Stenoparib, a dual PARP/Wnt pathway inhibitor, combined with temozolomide aims to improve upon previous PARP inhibitor combinations that showed ~40% response rates but had dose-limiting toxicity.
Key advantages of stenoparib include its ability to cross the blood-brain barrier, potentially treating both systemic tumors and brain metastases, and its unique tankyrase inhibition affecting the Wnt pathway involved in SCLC progression and treatment resistance. The trial will assess progression-free survival and determine the recommended Phase 2 dose during an initial safety lead-in phase.
Allarity Therapeutics (NASDAQ: ALLR) has announced a $5 million share repurchase program authorized by its Board of Directors, running through February 28, 2026. The company, currently in Phase 2 clinical trials, is developing stenoparib—a dual PARP/Wnt pathway inhibitor—for personalized cancer treatment using its Drug Response Predictor (DRP®) technology.
The repurchase program, which will be executed through open market transactions, reflects management's confidence in the company's direction and its commitment to shareholder value. As disclosed in November 2024, Allarity's cash position extends into 2026, allowing the company to proceed with the buyback without impacting its financial runway.
The company is preparing to initiate patient enrollment for stenoparib trials in advanced ovarian cancer, focusing on investigating its dual mechanisms as both a PARP inhibitor and Wnt pathway modulator.
Allarity Therapeutics (NASDAQ: ALLR) announced the complete dismissal of a securities class action lawsuit filed against the company in the United States District Court for the Southern District of New York. The lawsuit, originally filed on September 13, 2024, alleged false or misleading statements regarding the Dovitinib New Drug Application (NDA) regulatory prospects.
The case was dismissed with each party bearing its own legal costs, and notably, no settlement or payment was required from Allarity or its officers. The company, which is currently in Phase 2 clinical trials, is developing stenoparib—a dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary Drug Response Predictor (DRP®) technology.